2026-10-23T16:01:48Zhttps://gumushane-rdlopen.rawdatalibrary.net/oai/request

oai:gumushane-rdlopen.rawdatalibrary.net:gumushane/106892026-10-22T11:40:54Zopenairedrivercom_gumushane_10000col_gumushane_10001

Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life StudyTünbekici, SalihYuksel, Haydar cagatayAcar, CanerSahin, GoekhanOrman, SevalMajidova, NargizCoskun, AlperSeyyar, MustafaDilek, Mehmet siddikKara, MahmutDisli, Ahmet KursatDemir, TeyfikKolkiran, NagihanSahbazlar, MustafaDemirciler, ErkutKus, FatihAytac, AliMenekse, SerkanYucel, HakanBiter, SedatKoseci, TolgaUnsal, AhmetOzveren, AhmetSevinc, AlperGoker, ErdemGürsoy, Pinarregorafenibrecurrent glioblastomasafetyefficacytargeted therapyreal-worldBackground/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of <= 2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18-67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23-2.75) and a median overall survival of 4.1 months (95% CI: 3.52-4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0-1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.MDPI2025-01Articlehttps://rdlopen.rawdatalibrary.net/r/gumushane/10689https://doi.org/10.3390/cancers17010046enCANCERSinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://gumushane-rdlopen.rawdatalibrary.net/tr/items/gumushane/10689